SOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider Jurgi Camblong Sells 8,500 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) Chairman Jurgi Camblong sold 8,500 shares of the firm’s stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $7.26, for a total value of $61,710.00. Following the completion of the transaction, the chairman owned 3,387,150 shares of the company’s stock, valued at approximately $24,590,709. This represents a 0.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, October 5th, Jurgi Camblong sold 40,172 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.13, for a total value of $326,598.36.
• On Thursday, September 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.66, for a total transaction of $65,110.00.
• On Monday, August 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.61, for a total transaction of $64,685.00.
• On Friday, August 7th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.23, for a total transaction of $144,600.00.
• On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total transaction of $138,400.00.
• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.63, for a total transaction of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.29, for a total transaction of $153,356.49.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH opened at $7.29 on Friday. SOPHiA GENETICS SA has a 1 year low of $3.75 and a 1 year high of $8.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The stock has a market capitalization of $611.59 million, a PE ratio of -6.34 and a beta of 0.95. The company’s 50 day simple moving average is $7.98 and its two-hundred day simple moving average is $6.24.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). The firm had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. Analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds have recently bought and sold shares of SOPH. Maven Securities LTD purchased a new position in SOPHiA GENETICS in the 2nd quarter worth approximately $866,000. AXQ Capital LP purchased a new stake in shares of SOPHiA GENETICS during the 2nd quarter valued at $119,000. AWM Investment Company Inc. purchased a new stake in shares of SOPHiA GENETICS during the 2nd quarter valued at $9,809,000. Hennion & Walsh Asset Management Inc. bought a new stake in shares of SOPHiA GENETICS during the 2nd quarter worth $567,000. Finally, Royal Bank of Canada lifted its holdings in shares of SOPHiA GENETICS by 3,130.2% during the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after acquiring an additional 18,781 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. BTIG Research lifted their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of SOPHiA GENETICS in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.